AP872A - Azabicyclic carbamoyloxy mutilin derivatives for antibacterial use. - Google Patents

Azabicyclic carbamoyloxy mutilin derivatives for antibacterial use. Download PDF

Info

Publication number
AP872A
AP872A APAP/P/1997/001047A AP9701047A AP872A AP 872 A AP872 A AP 872A AP 9701047 A AP9701047 A AP 9701047A AP 872 A AP872 A AP 872A
Authority
AP
ARIPO
Prior art keywords
group
compound
formula
mutilin
azabicyclo
Prior art date
Application number
APAP/P/1997/001047A
Other versions
AP9701047A0 (en
Inventor
Andrew Kenneth Takle
Eric Hunt
Antoinette Naylor
Original Assignee
Smithkline Beecham Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9616305.0A external-priority patent/GB9616305D0/en
Priority claimed from PCT/EP1996/005874 external-priority patent/WO1997025309A1/en
Priority claimed from GBGB9712963.9A external-priority patent/GB9712963D0/en
Application filed by Smithkline Beecham Plc filed Critical Smithkline Beecham Plc
Publication of AP9701047A0 publication Critical patent/AP9701047A0/en
Application granted granted Critical
Publication of AP872A publication Critical patent/AP872A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D203/00—Heterocyclic compounds containing three-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D203/04—Heterocyclic compounds containing three-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D203/06—Heterocyclic compounds containing three-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D203/08—Heterocyclic compounds containing three-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/32—Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/32—Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C07C271/36—Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of rings other than six-membered aromatic rings with the nitrogen atom of at least one of the carbamate groups bound to a carbon atom of a ring other than a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/62—Compounds containing any of the groups, X being a hetero atom, Y being any atom, e.g. N-acylcarbamates
    • C07C271/64—Y being a hydrogen or a carbon atom, e.g. benzoylcarbamates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/62—Compounds containing any of the groups, X being a hetero atom, Y being any atom, e.g. N-acylcarbamates
    • C07C271/66—Y being a hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C281/00—Derivatives of carbonic acid containing functional groups covered by groups C07C269/00 - C07C279/00 in which at least one nitrogen atom of these functional groups is further bound to another nitrogen atom not being part of a nitro or nitroso group
    • C07C281/02—Compounds containing any of the groups, e.g. carbazates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C307/00—Amides of sulfuric acids, i.e. compounds having singly-bound oxygen atoms of sulfate groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C307/04—Diamides of sulfuric acids
    • C07C307/06—Diamides of sulfuric acids having nitrogen atoms of the sulfamide groups bound to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
    • C07C311/02—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C311/08—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/30—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/37—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • C07C311/38—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring having sulfur atoms of sulfonamide groups and amino groups bound to carbon atoms of six-membered rings of the same carbon skeleton
    • C07C311/39—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring having sulfur atoms of sulfonamide groups and amino groups bound to carbon atoms of six-membered rings of the same carbon skeleton having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/50—Compounds containing any of the groups, X being a hetero atom, Y being any atom
    • C07C311/52—Y being a hetero atom
    • C07C311/53—X and Y not being nitrogen atoms, e.g. N-sulfonylcarbamic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/44—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
    • C07C323/51—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C323/60—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton with the carbon atom of at least one of the carboxyl groups bound to nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C331/00—Derivatives of thiocyanic acid or of isothiocyanic acid
    • C07C331/02—Thiocyanates
    • C07C331/14—Thiocyanates having sulfur atoms of thiocyanate groups bound to carbon atoms of hydrocarbon radicals substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D203/00—Heterocyclic compounds containing three-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D203/04—Heterocyclic compounds containing three-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D203/06—Heterocyclic compounds containing three-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D203/16—Heterocyclic compounds containing three-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with acylated ring nitrogen atoms
    • C07D203/20—Heterocyclic compounds containing three-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with acylated ring nitrogen atoms by carbonic acid, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D211/62—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/40—Acylated substituent nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/70—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/79—Acids; Esters
    • C07D213/80—Acids; Esters in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/38—One sulfur atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D257/04—Five-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D261/18—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/10—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles
    • C07D271/113—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/36—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D277/70—Sulfur atoms
    • C07D277/76—Sulfur atoms attached to a second hetero atom
    • C07D277/80—Sulfur atoms attached to a second hetero atom to a nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/06—1,2,3-Thiadiazoles; Hydrogenated 1,2,3-thiadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/12—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles
    • C07D285/125—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • C07D295/084—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/088—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/20—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carbonic acid, or sulfur or nitrogen analogues thereof
    • C07D295/205—Radicals derived from carbonic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/20—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carbonic acid, or sulfur or nitrogen analogues thereof
    • C07D295/215—Radicals derived from nitrogen analogues of carbonic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/04—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D307/10—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/66—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/68—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
    • C07D317/62—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to atoms of the carbocyclic ring
    • C07D317/66—Nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/30—Hetero atoms other than halogen
    • C07D333/34—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D455/00—Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine
    • C07D455/02—Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine containing not further condensed quinolizine ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/20—Carbocyclic rings
    • C07H15/24—Condensed ring systems having three or more rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2603/00—Systems containing at least three condensed rings
    • C07C2603/56—Ring systems containing bridged rings
    • C07C2603/58—Ring systems containing bridged rings containing three rings
    • C07C2603/76—Ring systems containing bridged rings containing three rings containing at least one ring with more than six ring members
    • C07C2603/80—Ring systems containing bridged rings containing three rings containing at least one ring with more than six ring members containing eight-membered rings
    • C07C2603/82—Ring systems containing bridged rings containing three rings containing at least one ring with more than six ring members containing eight-membered rings having three condensed rings with in total fourteen carbon atoms and having a having a [5.4.3.0(1,8)] ring structure, e.g. pleuromutiline

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Compounds of formula (3), and pharmaceutically acceptable salts and derivatives thereof: in which: R.1 is vinyl or ethyl; and R2 is a group R3, R4CH2~, or R5R6C=CH-; wherein each of R3 and R4 is an azabicyclic ring system or R5 and R^ together with the carbon atom to which they are attached form an azabicyclic ring system, are useful in the prevention and treatment of microbial infections.

Description

NOVEL COMPOUNDS
The present invention relates to novel compounds, to processes for their preparation, to pharmaceutical compositions containing them aid to their use in medical therapy, particularly antibacterial therapy.
Pleuromutilin, the compound of formula (1), is a naturally occurring antibiotic which has antimycoplasmal activity and modest antibacterial activity. It has been shown that the antimicrobial activity can be improved by replacing the glycolic ester moiety at position 14 by an R-X-ChfyCCb- group, where R is an aliphatic or aromatic moiety and X is O, S, or NR' (H Egger and H Reinshagen, J Antibiotics, 1976, 29, 923). Tiamulin, the compound of formula (2), which is used as a veterinary antibiotic, is a derivative of this type (G Hogenauer in Antibiotics, Vol. V, part 1, ed. F E Hahn, Springer-Verlag, 1979, p.344).
AP/P/ 9 7/01047
P31583
ΑΡΰ00872
In this application, the non-conventional numbering system which is generally used in the literature (G Hogenauer, loc.cit.) is used.
We have found that certain novel pleuromutilin analogues containing a 14O-carbamoyl group, also have improved antimicrobial properties.
Accordingly, in its broadest aspect, the present invention provides a 14-0carbamoyl derivative of mutilin or 19, 20-dihydromutilin, in which the N-atom of the carbamoyl group is acylated by a group which includes an azabicyclic moiety.
More specifically, this invention provides a compound of general formula (3):
in which:
Rl is vinyl or ethyl; and is a group R3, R^CHg', or r5r6c=CH-; wherein each of R3 and R^ is an azabicyclic ring system or R^ and R^ together with the carbon atom to which they are attached form an azabicyclic ring system.
The azabicyclic ring system is a bridged or fused non-aromatic ring system attached via a bridgehead or non-bridgehead ring carbon atom and containing one bridgehead nitrogen atom as the sole hetero ring atom. The ring system contains between 5 and 10 ring atoms in each ring and is optionally substituted on carbon by up to 3 substituents. Suitable substituents include alkyl, alkyloxy, alkenyl and alkenyloxy, each of which may be carried by either a bridgehead or a non-bridgehead carbon atom. In addition, the bridgehead nitrogen atom may be substituted by oxygen, to form an N-oxide, or by alkyl, to
AP/P/ 97 / 0 10 47
P31583
AP Ο ϋ Ο 87 2 form a quaternary cation. The counterion may be a halide ion such as chloride or bromide, preferably chloride.
The azabicyclic ring system may for example be represented by formula (I):
wherein R7 represents one or more optional substituents as set out above and each of a, b and c is between 0 and 4, such that any one ring has between 5 and 10 ring atoms. The azabicyclic ring system additionally may contain one or more double bonds.
Particular azabicyclic groups include azabicyclo[2.2.2]octyl, azabicyclo [2.2.1 jheptyl, azabicyclo [3.2.1 joctyl, azabicyclo [4.4. Ojdecyl, quinuclidinyl, azabicyclo[3.2.1]octenyl, and azabicyclo[3.3.1]non-5-yl.
Alkyl and alkenyl groups referred to herein include straight and branched groups containing up to six carbon atoms and are optionally substituted by one or more groups selected from the group consisting of aryl, heterocyclyl, (Cp6)alkoxy, (Ci_g)alkylthio, aryl(Ci_6)aIkoxy, aryl(Ci_6)alkylthio, amino, mono- or di-(Ci_6)alkylamino, cycloalkyl, cycloalkenyl, carboxy and esters thereof, hydroxy, and halogen.
Cycloalkyl and cycloalkenyl groups referred to herein include groups having between three and eight ring carbon atoms and are optionally substituted as described hereinabove for alkyl and alkenyl groups.
When used herein, the term aryl means single and fused rings suitably containing from 4 to 7, preferably 5 or 6, ring atoms in each ring, which rings, may each be unsubstituted or substituted by, for example, up to three substituents.
£9010/76 /d/dV
P31583
APO00872
A fused ring system may include aliphatic rings and need include only one aromatic ring.
Suitable aryl groups include phenyl and naphthyl such as 1 -naphthyl or 2naphthyl.
Suitably any aryl group, including phenyl and naphthyl, may be optionally substituted by up to five, preferably up to three substituents. Suitable substituents include halogen, (Cj.gjalkyl, aryl, aryl(C)_6)alkyl, (Ci.g)alkoxy, (Ci_6)alkoxy(Ci_6)alkyI, halo(Ci_6)alkyl, arylfCj.gjalkoxy, hydroxy, nitro, cyano, azido, amino, mono- and di-A-(Ci_6)alkylamino, acylamino, arylcarbonylamino, acyloxy, carboxy, carboxy salts, carboxy esters, carbamoyl, mono- and di-yV-(Ci_6)alkylcarbamoyl, (Ci.gjalkoxycarbonyl, aryloxycarbonyl, ureido, guanidino, sulphonylamino, aminosulphonyl, (CJ.gjalkylthio, (Cj.g)alkyl sulphinyl, (Ci.gjalkylsulphonyl, heterocyclyl and heterocyclyl (C{ .gjalkyl. In addition, two adjacent ring carbon atoms may be linked by a (C3_5)alkylene chain, to form a carbocyclic ring.
When used herein the terms heterocyclyl and heterocyclic suitably include, unless otherwise defined, aromatic and non-aromatic, single and fused,. rings suitably containing up to four heteroatoms in each ring, each of which is selected from oxygen, nitrogen and sulphur, which rings, may be unsubstituted or substituted by, for example, up to three substituents. Each heterocyclic ring suitably has from 4 to 7, preferably 5 or 6, ring atoms. A fused heterocyclic ring system may include carbocyclic rings and need include only one heterocyclic ring.
Preferably a substituent for a heterocyclyl group is selected from halogen, (Ci_6)alkyl, aryl(Ci_6)alkyl, (CJ.gjalkoxy, (Ci_6)alkoxy(Ci_6)aIkyl, halo(Cj.
g)alkyl, hydroxy, amino, mono- and di-;V-(C j.gjalkyl-amino, acylamino, carboxy, carboxy salts, carboxy esters, carbamoyl, mono- and di-yV-(CJ _g)alkylcarbony 1, aryloxycarbonyl, (Ci_6)alkoxycarbonyl(Ci_6)alkyl, aryl, oxy groups, ureido, guanidino, sulphonylamino, aminosulphonyl, (Cpgjalkylthio,
AP/P/ 9 7 / 0 1 0 47
P31583
AP 0 0 0 8 7 2 (C]_g)alkylsulphinyl, (Cj.gjalkylsulphonyl, heterocyclyl and heterocyclyl(C j .gjalkyl.
In a further aspect the present invention provides a method for preparing compounds of the invention, which comprises reacting a compound of formula (4) where X is hydrogen or a hydroxyl protecting group, such as an acyl group, or a compound of formula (5), with an acyl isocyanate of formula RPCONCO, R4CH2CONCO, or r5r6c=CHCONCO:
Ot
Methods for preparing acyl isocyantes are described in the literature. For example, they may be prepared by reaction of an acid chloride (R^COCl, R4CH2COC1, or r5r6c=CHCOC1) with silver cyanate (e.g. as described by Murdock and Angier in J. Org. Chem., 1962, 27, 3317), tri-n-butyl tin isocyanate (e.g. as described by Akteries and Jochims, Chem. Ber., 1986,119, 83), or trimethylsilyl isocyanate (e.g. as described by Sheludyakov et al., J. Gen. Chem. USSR, 1977, 2061-2067) in an inert solvent such as benzene, toluene, chloroform, dichloromethane, or 1,2-di chloroethane; or reaction of a primary amide (R3CONH2, R4CH2CONH2, or R^R^C=CHCONH2), or yV,jV-bis(trimethylsilyl) 20 derivative thereof, with oxalyl chloride or phosgene in an inert solvent (e.g.
Speziale and Smith, J. Org. Chem., 1962,27, 3742; Kozyukov, et al., Zh Obshch Khim, 1983,53,2155).
We have found that the formation and reaction of the acyl isocyanate can be conveniently carried out in one process. This typically involves reaction of (4)
AP/P/ 9 7/01047
P31583
AP0U 0 8 7 2 or (5) with an acid chloride (as an acid-addition salt of the azabicyclic moiety, usually the hydrochloride salt) in the presence of silver cyanate and a tertiary base (e.g. triethylamine, dii'sopropyl ethylamine, pyridine), usually triethylamine, in an inert solvent (e.g. chloroform, dichloromethane, 1,2-dichloroethane).
More particularly, in one aspect the present invention provides a process for the preparation of a compound of formula (3) which comprises reacting a compound of formula (4) with a compound of formula R4COC1, R^CIUCOCl.-or r5r6c=CHCOC1 in the presence of silver cyanate and a base, such as triethylamine,wherein each of to R^ is protected where appropriate, and thereafter carrying out one or more of the following steps in any desired order:
• deprotecting a group X to generate a hydroxyl group at position 11, • deprotecting a protected group to , • converting one group R^ to R^ to another group R^ to R^, and • hydrogenating the vinyl group at position 12 to form an ethyl group.
Although it is possible to prepare compounds of formula (3) by reaction at the 14-hydroxyl in the known compound mutilin (X = H in formula (4)), in practice it is desirable to use an intermediate in which the 11-hydroxyl is protected.
Suitable compounds as formula (4) include 11-O-acyl mutilin derivatives,
e.g. mutilin 11-acetate (X = Ac in formula (4)) (A J Birch, C W Holzapfel, R W Richards, Tetrahedron (Suppl.), 1966, 8, Part II, 359) or mutilin 11dichloroacetate or mutilin 11 -trifluoroacetate. After formation of the 14-0carbamoyl derivative, the 11-O-acyl group may be removed by selective hydrolysis (e.g. using NaOH in MeOH).
In another aspect, the present invention provides a process for the preparation of a compound of formula (3) which comprises reacting a compound of formula (5) with a compound of formula R^COCl, R^CP^COCl, or r5r6c=CHCOCI in the presence of silver cyanate and a base, such as
AP/P/ 9 7 /01047
P31583
AP Ο Ο ϋ 8 7 2 triethylamine,wherein each of to R^ is protected where appropriate, and thereafter carrying out one or more of the following steps in any desired order:
• treating the product with acid to obtain a compound of formula (3) · deprotecting a protected group R^ to R^ , • converting one group R-> to R^ to another group R^ to R^, and • hydrogenating the vinyl group at position 12 to form an ethyl group.
Formula (5) is (3R)-3-deoxo-l l-deoxy-3-methoxy-1 l-oxo-4-epi-mutilin (H Berner, G Schulz and H Schneider, Tetrahedron, 1980, 36, 1807). After formation of the 14-carbamate , the intermediate may be converted into (3) by treatment with cone. HC1 or Lukas reagent (cone. HC1 saturated with ZnCl2) in dioxane.
For preparation of 19,20-dihydro analogues (compounds of formula (3) in which Rl = Et), before or after the carbamoylation, of a compound of formula (4) or (5), a vinyl group R^ can be reduced by hydrogenation over a palladium catalyst (e.g. 10% Palladium-on-carbon) in a solvent such as ethyl acetate, ethanol, dioxane, or tetrahydrofuran.
Suitable hydroxy, carboxy and amino protecting groups are those well known in the art and which may be removed under conventional conditions and without disrupting the remainder of the molecule. A comprehensive discussion of the ways in which hydroxy, carboxy and amino groups may be protected and methods for cleaving the resulting protected derivatives is given in for example Protective Groups in Organic Chemistry (T.W. Greene and P.G.M. Wuts, Wiley-Interscience, New York, 2nd edition, 1991). Particularly suitable hydroxy protecting groups include, for example, triorganosilyl groups such as, for instance, trialkylsilyl and also organocarbonyl and organooxycarbonyl groups such as, for instance, acetyl, allyloxycarbonyl, 4-methoxybenzyloxycarbonyl and 4nitrobenzyloxycarbonyl. Particularly suitable carboxy protecting groups include alkyl and aryl groups, for instance methyl, ethyl and phenyl. Particularly suitable
AP/P/ 9 7 / 0 1 0 47
P31583
ΑΡΟ 00 8 7 2 amino protecting groups include alkoxy carbonyl, 4-methoxybenzyloxycarbonyI and 4-nitrobenzyloxycarbonyl.
In cases where the intermediate of formula (4) ( such as X= acetyl) is used, a base-labile protecting group may conveniently be removed at the same time as the group X is deprotected. In cases when the intermediate of formula (5) is used, an acid-labile protecting group may conveniently be removed at the same time as the compound (5) is converted into the compound (3).
The azabicyclic ring system present in the compounds of the present invention may contain a chiral centre, and the compound of formula (3) may therefore comprise a mixture of diastereoisomers or a single diastereoisomer. A single diastereoisomer of formula (3) may be prepared by separating such a mixture of diastereoisomers which has been synthesised using a racemic *
- azabicyclic starting material, or by synthesis using an optically pure azabicyclic starting material.
The compounds of this invention may be in crystalline or non-crystalline form, and, if crystalline, may optionally be hydrated or solvated. When some of the compounds of this invention are allowed to crystallise or are recrystallised . from organic solvents, solvent of crystallisation may be present in the crystalline product. This invention includes within its scope such solvates. Similarly, some of the compounds of this invention may be crystallised or recrystallised from solvents containing water. In such cases water of hydration may be present in the crystalline product. This invention includes within its scope stoichiometric hydrates as well as compounds containing variable amounts of water that may be produced by processes such as lyophilisation.
The compounds according to the invention are suitably provided in substantially pure form, for example at least 50% pure, suitable at least 60% pure, advantageously at least 75% pure, preferably at least 85% pure, more preferably at least 95% pure, especially at least 98% pure, all percentages being calculated as weight/weight. An impure or less pure form of a compound according to the £ V 0 I 0 / £ 6 Zd/dY
P31583
APO00872 invention may, for example, be used in the preparation of a more pure form of the same compound or of a related compound (for example a corresponding derivative) suitable for pharmaceutical use.
The present invention also includes pharmaceutically acceptable salts and 5 derivatives of the compounds of the invention. Salt formation may be possible when one of the substituents carries an acidic or basic group. Salts may be prepared by salt exchange in conventional manner
Acid-addition salts of the azabicyclic moiety can be pharmaceutically acceptable or non-pharmaceutically acceptable. In the latter case, such salts may be useful for isolation and purification of the compound of formula (3), or intermediates thereto, and will subsequently be converted into a pharmaceutically acceptable salt or the free base. Pharmaceutically acceptable acid-addition salts include those described by Berge, Bighley, and Monkhouse, J. Pharm. Sci., 1977, 66, 1-19. Suitable salts include the hydrochloride, maleate, and methanesulphonate; particularly the hydrochloride.
It will also be understood that where the compound of formula (3) contains a free carboxy moiety, the compound of formula (3) can form a zwitterion.
The compounds of the present invention and their pharmaceutically acceptable salts or derivatives have antimicrobial properties and are useful for the treatment of microbial infections in animals, especially mammals,, including humans, in particular humans and domesticated animals (including farm animals). The compounds may be used for the treatment of infections caused by, for example, Gram-positive and Gram-negative bacteria and mycoplasmas, including, for example, Staphylococcus aureus, Staphylococcus epidermidis, Enterococcus faecalis, Streptococcus pyogenes, Streptococcus agalactiae, Streptococcus pneumoniae, Haemophilius sp., Neisseria sp., Legionella sp., Chlamydia sp., Moraxella catarrhalis, Mycoplasma pneumoniae, and Mycoplasma gallisepticum.
;P/P/ 9 7 / 0 1 0 47
P315S3
AF a ο Ο 8 7 2
The present invention provides a pharmaceutical composition comprising a compound of formula (3) or a pharmaceutically acceptable salt or derivative thereof together with a pharmaceutically acceptable carrier or excipient.
The present invention also provides a method of treating microbial 5 infections in animals, especially in humans and in domesticated mammals, which comprises administering a compound of formula (3) or a pharmaceutically acceptable salt or derivative thereof, or a composition according to the invention, to a patient in need thereof.
The invention further provides the use of a compound of the invention or a 10 pharmaceutically acceptable salt or derivative thereof in the preparation of a medicament composition for use in the treatment of microbial infections.
The compounds and compositions according to the invention may be formulated for administratioh’in any convenient way for use in human or veterinary medicine, by analogy with other antibiotics.
The compounds and compositions according to the invention may be formulated for administration by any route, for example oral, topical or parenteral. The compositions may, for example, be made up in the form of tablets, capsules, powders, granules, lozenges, creams, syrups, or liquid preparations, for example solutions or suspensions, which may be formulated for oral use or in sterile form for parenteral administration by injection or infusion.
Tablets and capsules for oral administration may be in unit dosage form, and may contain conventional excipients including, for example, binding agents, for example, syrup, acacia, gelatin, sorbitol, tragacanth, or polyvinylpyrrollidone; fillers, for example lactose, sugar, maize-starch, calcium phosphate, sorbitol or glycine; tabletting lubricants, for example magnesium stearate, talc, polyethylene glycol or silica; disintegrants, for example potato starch; and pharmaceutically acceptable wetting agents, for example sodium lauryl sulphate. The tablets may be coated according to methods well known in normal pharmaceutical practice.
AP/P/ 97 / 0 10 47
P31583
APO00872
Oral liquid preparations may be in the form of, for example, aqueous or oily suspensions, solutions, emulsions, syrups or elixirs, or may be presented as a dry' product for reconstitution with water or another suitable vehicle before use. Such liquid preparations may contain conventional additives, including, for example, suspending agents, for example sorbitol, methyl cellulose, glucose syrup, gelatin, hydroxyethyl cellulose, carboxymethyl cellulose, aluminium stearate gel or hydrogenated edible fats; emulsifying agents, for example lecithin, sorbitan monooleate or acacia; non-aqueous vehicles (which may include edible oils), for example almond oil, oily esters (for example glycerine), propylene glycol, or ethyl alcohol; preservatives, for example methyl or propyl p-hydroxybenzoate or sorbic acid; and, if desired, conventional flavouring and colour agents.
’Compositions according to the invention intended for topical administration may, for example, be in the form of ointments, creams, lotions, eye ointments, eye drops, ear drops, nose drops, nasal sprays, impregnated dressings, and aerosols, and may contain appropriate conventional additives, including, for example, preservatives, solvents to assist drug penetration, and emollients in ointments and creams. Such topical formulations may also contain compatible conventional carriers, for example cream or ointment bases, and ethanol or oleyl alcohol for lotions. Such carriers may constitute from about 1% to about 98% by weight of the formulation; more usually they will constitute up to about 80% by weight of the formulation.
Compositions according to the invention may be formulated as suppositories, which may contain conventional suppository bases, for example cocoa-butter or other glycerides.
Compositions according to the invention intended for parenteral administration may conveniently be in fluid unit dosage forms, which may be prepared utilizing the compound and a sterile vehicle, water being preferred. The compound, depending on the vehicle and concentration used, may be either
AP/P/ 9 7/01047
P31583
AP000872 suspended or dissolved in the vehicle. In preparing solutions, the compound may be dissolved in water for injection and filter-sterilised before being filled into a suitable vial or ampoule, which is then sealed. Advantageously, conventional additives including, for example, local anaesthetics, preservatives, and buffering agents can be dissolved in the vehicle. In order to enhance the stability of the solution, the composition may be frozen after being filled into the vial, and the water removed under vacuum; the resulting dry lyophilized powder may then be sealed in the vial and a accompanying vial of water for injection may be supplied to reconstitute the liquid prior to use. Parenteral suspensions may be prepared in substantially the same manner except that the compound is suspended in the vehicle instead of being dissolved and sterilisation canno t be accomplished by filtration. The compound may instead be sterilised by exposure to ethylene oxide before being suspended in the sterile’ vehicle. Advantageously, a surfactant or wetting agent is included in such suspensions in order to facilitate uniform distribution of the compound.
A compound or composition according to the invention may suitably be administered to the patient in an antimicrobially effective amount.
A composition according to the invention may suitably contain from 0.1% by weight, preferably from 10 to 60% by weight, of a compound according to the invention (based on the total weight of the composition), depending on the method of administration.
The compounds according to the invention may suitably be administered to the patient at a daily dosage of from 1.0 to 50 mg/kg of body weight. For an adult human (of approximately 70 kg body weight), from 50 to 3000 mg, for example about 1500 mg, of a compound according to the invention may be administered daily. Suitably, the dosage for adult humans is from 5 to 20 mg/kg per day. Higher or lower dosages may, however, be used in accordance with normal clinical practice.
r*».
CFi
EC <
P31583
AP000872
When the compositions according to the invention are presented in unit dosage form, each unit dose may suitably comprise from 25 to 1000 mg. preferable from 50 to 500 mg, of a compound according to the invention.
The following Examples illustrate the present invention.
Note on naming of pleuromutilin analogues
In the Examples, compound (a), which in the IUPAC system has the systematic name (15, 2R, 35, 45, 6R, 7R, 8R, 147?)-3,6-dihydroxy-2,4,7,14tetramethyl-4-vinyl-tricyclo[5.4.3.0l’8]tetradecan-9-one, is referred to using the trivial name mutilin and with the numbering system described by H Berner,
G Schulz, and H Schneider in Tetrahedron, 1981, 37, 915-919.
(a) IUPAC numbering (a) Mutilin numbering
Likewise, compound (b), which has the systematic name (17?, 2R, 45, 6R,
7R, 85, 97?, 147?)- 6-hydroxy-9-methoxy-2,4,7,14-tetramethyl-4-vinyltricyclo[5.4.3.o£8]tetradecan-3-one, is named as (37?)-3-deoxo-l l-deoxy-3methoxy-11-oxo-4-epz-mutilin; and compound (c), which has the systematic name (l-aza-bicyclo[2.2.2]octane-4-carbonyl)-carbamic acid (15,27?, 35, 45, 67?, 77?,
87?, 147?)-3-hydroxy-2,4,7,14-tetramethyl-9-oxo-4-vinyltricyclo[5.4.3.0£8]tetradec-6-yl ester, is named as (l-aza-bicyclo[2.2.2]octane-4carbonyl)-carbamic acid mutilin 14-ester.
AP/P/ 9 7/01047
P31583
AP000872
AP/F/ 97/01047
P31583
ΑΡΟ ο Ο 8 7 2
Example 1. (l-Aza-bicyclo[2.2.2]octane-4-carbonyl)-carbamic acid mutilin
14-ester
Step 1. (l-Aza-bicyclo[2.2.2]octane-4-carbonyI)-carbamic acid (3R)-3-deoxo5 ll-deoxy-3-methoxy-ll-oxo-4-epi-mutilin 14-ester
Using the process described in Example 87, Step 3, of PCT/EP96/05874, quinuclidine-4-carboxylic acid hydrochloride (Helvetica Chimica Acta, 1974, 57, 2332) (230 mg) and (3R)-3-deoxo-l 1-deoxy-3-methoxy-1 l-oxo-4-epi-mutilin (330 mg) were converted into the title compound, which was obtained as a white foam (160 mg); 1H NMR (CDC13) inter alia 1.90 (6H, dd, J 8, 7.4 Hz), 3.10 (6H, dd, J 8, 7.4 Hz)), 3.21 (3H, s), 5.00 (1H, d, J 17.5 Hz), 5.27 (1H, d, J 10.7 Hz), 5.77 (1H, d, J 10 Hz), 6.68 (1H, dd, J 17.5, 10.7 Hz), 7.85 (1H, broad s); MS(ES) m/z 515 (MH+).
Step 2. (l-Aza-bicycIo[2.2.2]octane-4-carbonyl)-carbamic acid mutilin 14ester
Using the process described in Example 87, Step 4, of PCT/EP96/05874, (1-aza20 bicyclo[2.2.2]octane-4-carbonyl)-carbamic acid (3R)-3-deoxo-l l-deoxy-3methoxy-1 l-oxo-4-epi-mutilin 14-ester (140 mg) was converted into the title compound, which was obtained as a white solid (86 mg); 1H NMR (CDC13) inter alia 0.73 (3H, d, J 6.7 Hz), 0.87 (3H, d, J 7 Hz), 1.17 (3H, s), 1.49 (3H, s), 1.68 (6H, dd, J 8, 7.3 z), 2.93 (6H, dd, J 8, 7.3 Hz), 3.34 (1H, dd, J 10, 6.6 Hz), 5.22 (1H, d, J 17.3 Hz), 5.36 (1H, d, J 11 Hz), 5.76 (1H, d, J 8.5 Hz), 6.54 (1H, dd, J
17.3, 11 Hz); MS(ES) m/z 501 (MH+).
L V 0 I 0 / L 6 /d/dV
P31583
AP Ο Ο Ο 8 7 2
Example 2. (l-Aza-bicyc!o[2.2.2]octane-4-carbonyl)-carbamic acid mutilin
14-ester hydrochloride (l-Aza-bicyclo[2.2.2]octane-4-carbonyl)-carbamic acid mutilin 14-ester (71 mg) was dissolved in ethyl acetate (5 ml)/ 1,4-dioxane (2 ml) and 4M HC1 in dioxane (0.2 ml) was added. The solution was concentrated to ca. 1 ml by evaporation of solvent under reduced pressure, and toluene (5 ml) was added to give a white precipitate. The precipitate was collected by filtration, washed with toluene (2 ml), and dried in vacuo to give the title compound as a white solid (79 mg); 1H NMR (D2O) inter alia 0.69 (3H, d, J 6 Hz), 0.92 (3H, d, J 6.8 Hz), 1.15 (3H, s),
I. 39 (3H, s), 2.16 (6H, dd, J 8.2, 7.5 Hz), 3.42 (6H, dd, J 8.2, 7.5 Hz), 3.58 (1H, d, J 6 Hz), 5.20 (1H, d, J 17.5 Hz), 5.28 (1H, d, J 11.1 Hz), 5.68 (1H, d, J 8.1 Hz), 6.36 (1H, dd, J 17.5, 11.1 Hz).
Example 3 (l-Aza-bicyclo[2.2.1]heptane-4-carbonyl)-carbamic acid mutilin 14-ester
Step 1. (l-Aza-bicyclo[2.2.1]heptane-4-carbonyI)-carbamic acid (3R)-320 deoxo-ll-deoxy-3-methoxy-ll-oxo-4-epi-mutilin 14-ester
Using the process described in Example 87, Step 3, of PCT/EP96/05874, 1azabicyclo[2.2.1]heptane-4-carboxylic acid hydrochloride (Chemical Abstracts, 1989, 110, 95016) (700 mg) and (3R)-3-deoxo-l l-deoxy-3-methoxy-1 l-oxo-425 epi-mutilin (1 g) were converted into the title compound, which was obtained as a white solid (330 mg); 1H NMR (CDC13) inter alia 2.05 (4H, m), 2.72 (4H, m), 3.08 (2H, m), 3.22 (3H, s), 3.44 (1H, m), 5.02 (1H, d, J 17.5 Hz), 5.30 (1H, d, J
II. 6 Hz), 5.80 (1H, d, J 9.9 Hz), 6.69 (1H, dd, J 17.5, 11.6 Hz). 7.48 (1H, s); MS(ES)m/z501 (MH+).
AP/P/ 9 7/01047
P31583
Step 2. (l-Aza-bicyclo[2.2.1]heptane-4-carbonyI)-carbanric acid mutilin 14ester
AP000972
Using the process described in Example 87, Step 4, of PCT/EP96/05874, (1-Aza5 bicvclo[2.2.1]heptane-4-carbonyl)-carbamic acid (3R)-3-deoxo-l l-deoxv-3methoxy-1 l-oxo-4-epi-mutilin 14-ester (300 mg) was converted into the title compound, which was obtained as a white solid (250 mg); 1H NMR (CDC13) inter alia 2.28 (4H, m), 3.06 (2H, m), 3.37 (1H, broad s), 5.24 (1H. dd, J 17,3, 1.4 Hz), 5.38 (1H, dd, J 11, 1.4 Hz), 5.78 (1H, d, J 8.5 Hz), 6.64 (1H, dd, J 17.3, 11
Hz), 7.38 (1H, s); MS(EI) m/z 486 (M+); Found: 486.3085, C28H42N2O5 requires 486.3094.
Example 4. {(3S,4R)-l-Aza-bicyclo[2.2.1]heptane-3-carbonyI}-carbamic acid mutilin 14-ester
Step 1. {(3S,4R)-l-Aza-bicyclo[2.2.1]heptane-3-carbonyl}-carbamic acid (3R)-3-deoxo-ll-deoxy-3-methoxy-ll-oxo-4-epi-mutilin 14-ester (3R)-3-Deoxo-ll-deoxy-3-methoxy-l l-oxo-4-epi-mutilin (490 mg, 1.46 mmol) was combined with (3S,4R)-l-azabicyclo[2.2.1]heptane-3-carbonyl chloride (280 mg, 1.46 mmol) and silver cyanate (550 mg, 3.67 mmol) in dry dichloromethane (20 ml). Triethylamine (0.20 ml, 1.46 mmol) was added and the reaction stirred at room temperature for 16 hours in subdued light and under an atmosphere of argon. The mixture was filtered through Kieselguhr and the filtrate washed with saturated aqueous sodium hydrogen carbonate (x2) and brine. After drying (MgSOq.) purification was accomplished by chromatography on silica gel eluting with 4% (9:1 methanol:ammonia (35%)) in dichloromethane to yield the title compound (276 mg, 38%); nmax (CH2C12) 3383, 2981, 1780, 1749, 1698, 1460
AP/P/ 9 7/01047
P31583
APO00872 and 1374cm-l; MS (El) m/z 500 (M+). Found: 500.3248, C29H44N2O5 requires 500.3250.
Step 2.{(3S,4R)-l-Aza-bicyclo[2.2.1]heptane-3-carbonyl}-carbamic acid mutilin 14-ester
The product of Step 1 (260 mg, 0.52 mmol) in dioxane (3 ml) was treated with cone. HC1 (3 ml) and the reaction stirred at room for 30 minutes. The solution · was diluted with water and washed with dichloromethane (x2). The aqueous phase was basified with saturated aqueous sodium hydrogen carbonate and the product extracted into dichloromethane.. The organic phase was dried (MgSO4) and concentrated to yield the title compound (187 mg, 74%); nmax (CH2C12) 3386,2962, 1782, 1735,1699 and 1467cm-l; 1H NMR (d6-DMSO) 0.63 (3H, d, 'j 6.6Hz), 0.81 (3H, d, J 7.0Hz), 1.05-3.12 (29H, m) including 1.09 (3H, s) and 1.42 (3H, s), 4.52 (1H, d, J 6.0Hz, exch), 5.03-5.12 (2H, m), 5.51 (1H, d, J 7.8Hz),
6.21 (1H, dd, J 17.7, 11.1Hz), 10 40 (1H, bs); MS(CI) m/z 487 (MH+).
Example 5.{(3S,4R)-l-Aza-bicyclo[2.2.1]heptane-4-carbonyl}-carbamic acid 14-deoxy-19,20-dihydro-mutilin 14-ester
A solution of {(3S,4R)-l-aza-bicyclo[2.2.1]heptane-4-carbonyl}-carbamic acid mutilin 14-ester (95 mg, 0.20 mmol) in 1:1 ethanol:tetrahydrofuran (10ml) was hydrogenated for 12 hours over 10% palladium on carbon (90mg). The solution was filtered through celite and the solvent evaporated in vacuo to yield the title compound (85 mg, 87%); nmax (KBr) 3421, 2957, 1772, 1733, 1702 and
1464cm-l; 1H NMR (d6-DMSO) inter alia 0.68 (3H, d, J 7.1Hz), 0.82 (3H, d, J
6:8Hz), 4.46 (1H, d, J 5.9Hz), 5.46 (1H, d, J 7.6Hz), 10 53 (1H, bs); MS (El) m/z 488 (M+). Found: M+, 488.3256; C28H44N2O5 requires 488.3250.
AP/P/ 9 7 / 0 1 0 47
P31583
ΑΡΟ 0 0 8 7 2
Example 6. (l-Aza-bicycIo[2.2.2]octane-4-carbonyI)-carbamic acid 14-deoxy19,20-dihydro-mutilin 14-ester
A solution of (l-aza-bicyclo[2.2.2]octane-4-carbonyl)-carbamic acid mutilin 14ester (100 mg, 0.20 mmol) in 2:1 tetrahydro furan: ethanol (30ml) was hydrogenated for 1 hour over 10% palladium on carbon (lOmg). The solution was filtered through celite and the solvent evaporated in vacuo to yield the title compound as a white solid (90 mg, 90%); nmax(CH2C12) 2960, 1782, 1733, 1716 and 1479cm-1; 1H NMR (CDC13) inter alia 0.69 (3H, d, J 6.6Hz), 3.42 (1H, d, J 5.9Hz), 5.61 (1H, d, J 8.2Hz), 7.37 (1H, bs); MS (El) m/z 502 (M+). Found: M+,
502.3411; C29H46N2O5 requires 502.3407.
*
Example 7. (l-Aza-bicyclo[2.2.2]octane-3-carbonyl)-carbamic acid mutilin 15 14-ester
Step 1. (1-Aza-bicyclo [2.2.2] octane-3-carbonyl)-carbamic acid (3R)-3-deoxoll-deoxy-3-methoxy-ll-oxo-4-epi-mutiIin 14-ester
Quinuclidine-3-carboxylic acid was converted to the acid chloride hydrochloride by the procedure described in Example 161 of PCT/EP96/05874. This acid chloride was then reacted with (3R)-3-deoxo-l 1-deoxy-3-methoxy-1 l-oxo-4-epimutilin (1.002 g) by the procedure outlined in Example 161 of PCT/EP96/05874, to yield the title compound as a colourless foam (1.116 g) after silica gel column chromatography; MS (ES) m/z 515 (MH+).
AP/P/ 9 7/01047
P31583
APO 008 7 2
Step 2. (l-Aza-bicyclo[2.2.2] octane-3-carbonyI)-carbamic acid mutilin 14ester
The product from Step 1, (1.13 g) in 1,4-dioxan (12 ml) was stirred at room temperature for 7 h with cone, hydrochloric acid (5 ml). The solution was then diluted with ethyl acetate and neutralized with saturated sodium hydrogen carbonate solution. The organic solution was washed with saturated sodium chloride solution, dried (MgSO4) and evaporated to yield the crude product. After purification by silica gel chromatography, eluting with a gradient of 0-20% 9:1 methanol/35% ammonia solution in dichloromethane, the title compound was isolated as a white solid, (0.340 g). This solid, which was a mixture of two *
diastereoisomers, was digested in hot ethyl acteate and the resulting white solid was collected by filtration to yield one pure diastereoisomer of the title compound (0.140 g); IH NMR inter alia (CDC13) 0.75 (3H, d, J6.5 Hz), 0.90 (3H, d,
J7.0Hz), 1.20 (3H, s), 1.40 (3H, s), 2.70-3.10 (5H, m), 3.20 - 3.42 (3H, m), 5.155.40 (2H, ddd), 5.70 (IH, d, J8.3Hz), 6.50 (IH, dd, J10.95, 17.4Hz) and 7.40 (IH, s); MS (ES) m/z 501 (MH+). The mother liquors contained predominantly the other diastereoisomer of the title compound ( 0.200 g); IH NMR inter alia (CDC13) 0.75 (3H, d, J6.5 Hz), 0.90 (3H, d, J7.0Hz), 1.20 (3H, s), 1.41 (3H, s),
2.12 - 2.4 (3H, m), 2.70-3.10 (5H, m), 3.24 - 3.42 (3H, m), 5.15-5.45 (2H, m),
5.69 (IH, d, J8.3Hz), 6.50 (IH, dd, J11.0, 17.35Hz) and 7.40 (IH, s); MS (ES) m/z 501 (MH+).
Example 8.{(3S,4R)-l-Aza-bicyclo[2.2.1]heptane-3-carbonyl}-carbamic acid mutilin 14-ester hydrochloride
A solution of {(3S,4R)-l-aza-bicyclo[2.2.1]heptane-3-carbonyl}-carbamic acid mutilin 14-ester (1.0 g; 2.06 mmol) in acetone (100 ml) was treated with 1M HC1
AP/P/ 9 7 / 0 1 0 4 7
P31583
APO00872 in diethyl ether (4.2 ml; 4.20 mmol). The solution was stirred for 1 hour at room temperature and then concentrated in vacuo. The residue was triturated with diethyl ether to yield the title compound as a white solid (1.02 g, 95%); nmax (KBr) 3421, 2924, 1772, 1734, 1704 and 1465cm-1; 1HNMR(D2O) inter alia
0.62 (3H, d, J 6.0Hz), 0.90 (3H, d, J 6.9Hz), 5.22 (2H, dd, J 16.7, 11.1Hz), 5.61 (1H, d, J 8.1Hz), 6.35 (1H, dd, J 17.5, 11.1Hz).
Example 9. (l-Aza-bicyclo[3.2.1]octane-5-carbonyl)-carbamic acid mutilin 14-ester
Step 1. (l-Aza-bicyclo[3.2.1]octane-5-carbonyI)-carbamic acid (3R)-3-deoxoll-deoxy-3-methoxy-ll-oxo-4-epi-mutilin 14-ester
Triethylamine (0.58 ml, 4.2 mmol) was added to a strirred mixture of racemic 1azabicyclo[3.2.1]octane-5-carbonyl chloride hydrochloride (4 mmol), (3R)-315 deoxo-11-deoxy-3-methoxy-1 l-oxo-4-epi-mutilin (668 mg, 2 mmol) and silver cyanate (600 mg) in dichloromethane (25 ml). The mixture was stirred overnight at room temperature, filtered and the filtrate evaporated to dryness. The crude product was purified by chromatography on silica gel, eluting with 35% ammonia solutiommethanokdichloromethane 1:9:90 to give the title compound as a white solid (480 mg), Rf 0.1; 1H NMR (CDC13) inter alia 7.4 (1H, br s), 5.79 (1H, d, J 10), 3.21 (3H, s), 2.75-3.0 (6H, m); MS (+ve ion electrospray) m/z 515 (30%, MNH4+), m/z 556 (100%, M+H+MeCN+).
Step 2.(l-Aza-bicyclo[3.2.1]octane-5-carbonyl)-carbamic acid mutilin 1425 ester
The product of Step 1 (480 mg, 0.93 mmol) was dissolved in dioxan (2.5 ml) and cone hydrochloric acid (2.5 ml) was added slowly with cooling in an ice bath. The clear solution was stirred at room temperature for 4 hours and then diluted with tfrot 0/Z6 /d/dV
P31583
ΑΡΟ 0 0 8 7 2 water and basified by addition of sodium carbonate. The mixture was extracted with ethyl acetate and washed with brine. Drying (MgSO4) and evaporation gave a crude product which was purified by chromatography on silica gel eluting with 35% ammonia solution:methanol:dichloromethane 1:9:90, giving two diastereoisomers of the title compound as a white solid (274 mg, 58%); Rf 0.08; n max (CHC13) 2962, 1772, 1736m, 1628 cm-1; 1H NMR (CDC13) inter alia 7.58 (1H, br s), 6.51 (1H, dd, J 17, 11), 5.75 (1H, d, J 8.4), 5.34 (1H, dd, J 11, 1.25), 5.19 (1H, d, J 17, 1.25), 3.36 (1H, br), 3.08-3.2 (lH,m), 2.7-3.05 (5H, m); MS (+ve ion electrospray) m/z 501 (100%, MH+), MS (-ve ion electrospray) m/z 499 (100%, M-H-).
Example 10. (l-Aza-bicyclo[2.2.2]octane-2-carbonyl)-carbamic acid mutilin 14-ester
Step 1. (l-Aza-bicyclo[2.2.2]octane-2-carbonyl)-carbamic acid (3R)-3-deoxoll-deoxy-3-methoxy-ll-oxo-4-epi-mutilin 14-ester
Triethylamine (0.2 ml, 1.5 mmol) was added to a strirred mixture of racemic 1azabicyclo[2.2.2]octane-2-carbonyl chloride hydrochloride (ca 3 mmol), (3R)-320 deoxo-1 l-deoxy-3-methoxy-l 1-oxo-4-epi-mutilin (501 mg, 1.5 mmol) and silver cyanate (225 mg) in dichloromethane (10 ml). The mixture was stirred overnight at room temperature, filtered and the filtrate diluted with dichloromethane and washed with aq sodium bicarbonate and with brine. Drying (MgSO4) and evaporation gave a crude product which was purified by chromatography on silica gel, eluting with ethyl acetate: n-hexane 1:1. The title compound was obtained as a colourless gum (220 mg), Rf 0.12.
AP/P/ 9 7/01047
P31583
APO 00 8 7 2
Step 2. (l-Aza-bicyclo[2.2.2]octane-2-carbonyl)-carbamic acid mutilin 14ester
The product of Step 1 (200 mg) was dissolved in dioxan (2 ml) and cone hydrochloric acid (2 ml) was added slowly with cooling in an ice bath.. The clear solution was stirred at room temperature for 3 hours and then diluted with water and basified by addition of sodium bicarbonate. The mixture was extracted with ethyl acetate and washed with brine. Drying (MgSO4) and evaporation gave a crude product which was purified by chromatography on silica gel eluting with 5% methanol in chloroform, giving two diastereoisomers of the title compound as a white foam (135 mg, 69%); Rf 0.08; nmax (CHC13) 3309, 2946, 1780, 1735m, 1713 cm-1; MS (+ve ion electrospray) m/z 501 (22%, MH+), MS (-ve ion * electrospray) m/z 499 (100%, Μ- H-).
Example 11 {(3R,4S)-l-Aza-bicycIo[2.2.1]heptane-3-carbonyl}-carbamic acid mutilin 14ester
Step 1. {(3R,4S)-l-Aza-bicycIo[2.2.1]heptane-3-carbonyl}-carbamic acid (3R)-3-deoxo-ll-deoxy-3-methoxy-ll-oxo-4-epi-mutilin 14-ester
Ethyl (3R,4S)- l-azabicyclo[2.2.1]heptane-3-carboxylate (2.0g, I.F. Cottrell, D. Hands, D.J. Kennedy, K.J. Paul, S.H.B. Wright and K. Hoogsteen, J. Chem. Soc.
Perkin Trans. /, 1991, 1091-1097) was dissolved in concentrated hydrochloric acid and heated under reflux for 5 hours. After cooling the solution was evaporated under reduced pressure and the residue re-evaporated from toluene (x3). Drying over phosphorous pentoxide and trituration with cold ethyl
AP/P/ 9 7/01047
P31583
APO00872 acetate/methanol gave the hydrochloride salt of (3R,4S)-1azabicyclo[2.2.1]heptane-3-carboxylic acid (1.2g).
Using the process of Example 161 Step 1 of PTC/EP96/05874 (3R,4S)-1azabicyclo[2.2.1]heptane-3-carboxylic acid hydrochloride (890mg) and (3R)-3-deoxo-1 l-deoxy-3-methoxy-11-oxo-4-epi-mutilin (1.67g) were converted to the title compound, which was obtained as a colourless solid (1.28g, 51%): 1H NMR (CDC13) inter alia 0.86 (3H, d, J 7.0Hz), 1.01 (3H, d, J 6.3Hz), 1.21 (3H,.s), 1.24 (3H, s), 3.23 (3H, s), 5.05 (1H, d, J 17.5Hz), 5.34 (1H, d, J 10.7Hz), 5.76 (1H, d, J 10.0Hz), 6.62 (1H, dd, J 17.5, 10.7Hz), 7.75-7.85 (1H, br exch);
MS(Electrospray) m/z 501 (MH+).
Step 2. {(3R,4S)-l-Aza-bicyclo[2.2.1]heptane-3-carbonyl}-carbamic acid «r mutilin 14-ester
The product of Step 1 (501 mg) in dioxane (5 ml) was treated with concentrated hydrochloric acid (5 ml) and the reaction stirred at room for 3 hours. The solution was diluted with water and washed with ethyl acetate. The aqueous phase was basified with saturated aqueous sodium hydrogen carbonate and the product extracted into chloroform.. The organic phase was washed with water and saturated sodium chloride solution, dried (MgSO4) and concentrated. Purification of the residue by chromatography on silica gel eluting with chloroform/methanol/35% aqueous ammonia solution (20:1:0.1) gave the title compound as a colourless solid (380 mg, 78%): [a]j)20 q° (c q 5· EtOH); nmax (CH2C12) 3386, 2962, 1782, 1735, 1699 and 1467cm-l; 1HNMR (CDC13) inter alia 0.76 (3H, d, J 6.5Hz), 0.90 (3H, d, J 6.8Hz), 1.20 (3H, s), 1.45 (3Ή, s), 5.24 (1H, dd, J 17.3Hz), 5.38 (1H, d, J 11.0Hz), 5.73 (1H, d, J 8.5Hz), 6.49 (1H, dd, J 17.3, 11.0Hz), 7.70-7.90 (1H, br exch); MS (Electrospray) m/z 487 (MH+).
AP/P/ 97/01047
P31583
APO00872
Example 12 {(3R,4S)-l-Aza-bicyclo[2.2.1]heptane-3-carbonyl}-carbamic acid mutilin 145 ester hydrochloride
A solution of {(3R,4S)-l-aza-bicycIo[2.2.1]heptane-3-carbonyl}-carbamic acid mutilin 14-ester (200mg) in acetone (15 ml) was treated with 1M hydrogen chloride in diethyl ether (0.8 ml). The solution was stirred for 1 hour at room temperature. The resulting solid was collected washed with diethyl ether and dried to give the title compound as a colourless solid (200mg, 93%): [oc]p)20 -17.40 (c. 0.5; EtOH); δ(ϋ2Ο) inter alia 0.62 (3H, d, J 5.8 Hz), 0.85 (3H, d, J 7.0 Hz), 1.08 (3H, s), 1.32 (3H, s), 5.13 (1H, d, J 17.5 Hz), 5.20 (1H, d, J 11.0 Hz), 5.56 (1H, d, J 8.0 Hz), 6.30 (1H, dd, J 17.5 and 11.0 Hz); MS (Electrospray) m/z 487 (MH+15 HC1, 100%).
Example 13 {(3R,4R)-l-Aza-bicyclo[2.2.1]heptane-3-carbonyl}-carbamic acid mutilin 1420 ester hydrochloride
A suspension of (3R,4R)-l-azabicyclo[2.2.1]heptane-3-carboxylic acid hydrochloride (1.91 g, crude, containing NaCl, prepared according to G.A.
Showell, R. Baker, J. Davies, R. Hargreaves, S.B. Freedman, K. Hoogsteen, S.
Patel and R.J. Snow, J. Med. Chem. (1992), 35, 911-916) in dichloromethane (25 ml) was stirred under argon and treated with DMF (2 drops) and oxalyl chloride (1.56 ml). After 3 hours the solvent was evaporated, benzene (20 ml) added and evaporated, and dry dichloromethane (25 ml) added. The suspension was stirred under argon and treated with (3R)-3-deoxo-l l-deoxy-3-methoxy-1 l-oxo-4-epi30 mutilin (1,64g, prepared according to H. Berner, G. Schulz and H. Schneider, Tetrahedron (1980), 36, 1807), silver cyanate (925 mg) and triethylamine (0.86 ml). After 14 hrs saturated aqueous NaHCC>3 (25 ml) was added and stirred vigorously. The mixture was filtered through celite, the layers separated and the organic layer dried and evaporated. The residue was chromatographed on silica,
AP/P/ 9 7 / 0 1 0 47
Ρ31583
APO00872
CO eluting with dichloromethane/methanol/35% aqueous NHqOH (19:1:0.1) to yield {(3R,4R)-1 -aza-bicyclo[2.2.1 ]heptane-3-carbonyl} -carbamic acid (3R)-3-deoxo1 l-deoxy-3-methoxy-11-oxo-4-epi-mutilin 14-ester (0.88g): umax (CHCl3)3393, 1781, 1752, 1697, 1466cm'l; MS(+ve ion electrospray)m/z 501. (MH+, 100%). ·
This material was suspended in dioxan (12 ml), stirred, ice-cooled and treated with cone. HC1 (8 ml). After 5 mins, the cooling bath was removed and the solution left for 4 hours. Ethyl acetate (30 ml) and water (30 ml) were added, followed by solid NaHCOg portionwise until basic. The layers were separated and the organic layer dried and evaporated. The residue was taken up in ethyl acetate (20 ml) and treated with a 1M solution of HC1 in ether (3.5 ml), the solvent evaporated and the residue triturated under ether. Filtration gave the title compound as a white solid (660 mg): [α.]ρ)“θ + 2.8° (c. 0.5; EtOH); omax (CHCI3) 3548, 3432, 2429 (broad), 2361 (broad), 1724, 1581 cm'1; δ (DMSO) inter alia 0.65 (3H, d, J6.3 Hz), 0.82 (3H, d, J 6.8 Hz), 2.41 (1H, s), 4.58 (1H, broad s, disappears on D2O exchange), 5.0-5.2 (2H, m), 5.49 (1H, d, J 7.5 Hz), 6.23 (1H, dd, J 11 and 17.5 Hz), 10.68 (1H, s, disappears on D2O exchange), 10.78 (1H, s, disappears on D2O exchange); MS (+ve ion electrospray) m/z 487 (MH+-HC1, 100%).
The following compounds were prepared in a similar manner to Example
13:
Example 14 {(3S,4S)-l-Aza-bicyclo[2.2.1]heptane-3-carbonyl}-carbamic acid mutilin 1425 ester hydrochloride (3S,4S)-l-azabicyclo[2.2.1]heptane-3-carboxylic acid hydrochloride was prepared according to G.A. Showell, R. Baker, J. Davies, R. Hargreaves, S.B. Freedman,
K. Hoogsteen, S. Patel and R.J. Snow, J. Med. Chem. (1992), 35, 911-916. The 30 free base {(3S,4S)-l-aza-bicyclo[2.2.1]heptane-3-carbonyl}-carbamic acid mutilin 14-ester was chromatographed on silica, eluting with dichloromethane/methanol/35% aqueous NH4OH (19:1:0.1) before conversion to the hydrochloride. The title compound was obtained as a white solid: [a]£)20 +
11° (c. 0.5; EtOH); umax (CDCI3) 3695, 3387, 2426 (broad), 2360 (broad), 1736, 5 1711, 1602 cm'l; 5(DMSO) inter alia 0.64 (3H, d, J 6.3 Hz), 0.81 (3H, d, J 6.8
AP/P/ 9 7 / 0 1 0 47
P31583
APO00872
Hz), 2.40 (IH, s), 4.57 (IH, d, J 5.8 Hz), disappears on D2O exchange), 5.0-5.2 (2H, m), 5.49 (IH, d, J 7.8 Hz), 6.20 (IH, dd, J 8.6 and 17.5 Hz), 10.68 (IH, s, disappears on D2O exchange), 10.78 (IH, s, disappears on D2O exchange) MS (ammonia chemical ionisation) m/z 487 (MH+-HC1, 100%).
Example 15 (l-Aza-bicyclo[4.4.0]decane-4-carbonyl)-carbamic acid mutilin 14-ester hydrochloride (equatorial isomers)
The title compound was prepared from the equatorial isomer of 1-azabicyclo [4.4.0]decane-4-carboxyIic acid hydrochloride (P.A. Wyman et al, Bioorg. and Med. Chem. (1996), 4 255-261) and isolated as a white solid (35% overall): δ (DMSO) inter alia 0.63 (3H, d, J 6.3 Hz), 0.82 (3H, d, J 6.3 Hz), 4.55 (IH, d, J
5.8 Hz, disappears on D2O exchange) 5.03-5.13 (2H, m), 5.50 (IH, d, J 7.8 Hz),
6.21 (IH, dd, J 11.3 and 17.7 Hz), 10.1’(lH, broad s, disappears on D?O exchange), 10.52 (IH, s, disappears on D2O exchange); MS (+ve ion electrospray) 529 (MH+, 100%).
Example 16 (l-Aza-bicyclo[4.4.0]decane-4-carbonyl)-carbamic acid mutilin 14-ester hydrochloride (axial isomers)
The title compound was prepared from the axial isomer of 1azabicyclo[4.4.0]decane-4-carboxylic acid hydrochloride (P.A. Wyman et al, Bioorg. Med. Chem., (1996), 4, 255-261) and isolated as a white solid (6% overall yield): δ (DMSO) inter alia 0.63 (3H, d, J 6.3 Hz), 0.82 (3H, d, J 6.4 Hz), 3.43 (IH, t collapses to d on D2O exchange, J 5.3 Hz), 4.54 (IH, d, J 6 Hz, disappears on D2O exchange), 5.03-5.15 (2H, m), 5.50 (IH, d, J 8 Hz), 6.21 (IH, dd, J 11.3 Hz, 17.7 Hz), 10.12 (IH, broad s, disappears on D2O exchange), 10.52 (IH, s, disappears on D2O exchange); MS (+ve ion electrospray) m/z 529 (MH+, 100%)
AP/P/ 9 7/01047
P31583
Example 17 {(l-Aza-bicyclo[4.4.0]dec-4-yI)-acetyl}-carbamic acid mutilin 14-ester
Equatorial ethyl l-azabicyclo[4.4.0]dec-4-yl-acetate (US patent 3692791) was hydrolysed with 8M hydrochloric acid (1 day at room temp.). The resulting equatorial (l-azabicyclo[4.4.0]dec-4-yl)-acetic acid hydrochloride was used to prepare the title compound as a solid (21% overall): 6(CDCl3) inter alia 5.17 (1H. d, J 17.5 Hz), 5.31 (1H, d, J 12.5 Hz), 5.63 (1H, d, J 7.5 Hz), 6.41 (1H, dd, J 17.5 and 12.5 Hz), 7.27 (1H, s); MS (+ve ion electrospray) m/z 543 (MH+, 100%).
Example 18 (l-Aza-bicycIo[3.2.1]oct-3-ene-3-carbonyl)-carbamic acid mutilin 14-ester
The title compound was prepared from l-azabicyclo[3.2.1]oct-3-ene-3-carboxylic* acid hydrochloride (S.M. Bromidge et al, Bioorg. and Med. Chem. Letters, (1994), 4, 1185-1190) to give a white solid (12% overall): δ (CDCI3) inter alia 0.76 (3H, d, J 7.5 Hz), 0.88 (3H, d, J 5 Hz), 3.95 (1H, d, J 17.5 Hz), 5.21 (1H, dd,
J 17.5 Hz, 2 Hz), 5.36 (1H, dd, J 10 Hz, 2Hz), 5.78 (1H, d, J 7.5 Hz), 6.52 (1H, dd, J 17.5 Hz, 10 Hz), 6.91 (1H, d, 7.5 Hz), 7.41 (1H, s); MS (+ve ion electrospray) m/z 499 (MH+, 100%).
Example 19 (l-Aza-bicyclo[3.3.1]nonane-5-carbonyl)-carbamic acid mutilin 14-ester
The title compound was prepared from l-azabicyclo[3.3.1]nonane-5-carboxylic acid (US patent 573216, July 1992) as a solid (19% overall): δ (CDCI3) inter alia
3.27 (1H, d), 5.12 (1H, dd), 5.27 (1H, dd), 5.68 (1H, d), 6.46 (1H, dd); MS (+ve ion electrospray) m/z 515 (MH+) (\P/P7 9 7 / 0 1 0 47
P31583
A? Ο Ο Ο 8 7 2
Example 20 {(l-Aza-bicyclo[2.2.2]oct-3-yIidene)-acetyl}-carbamic acid mutilin 14-ester
3-Ethoxycarbonylmethylene-l-azabicyclo[2.2.2]octane (E,Z mixture; L.N. Yakhontov, L.I. Mastafanova, M.V. Rubstov, Zh. Obshch. Khim. (1963). 33. 3211-3214) was hydrolysed with 8M hydrochloric acid (2 days room temp, followed by 1 hour reflux). The resulting (l-aza-bicyclo[2.2.2]oct-3-ylidene)acetic acid (E, Z mixture) was used to prepare the title compound as a solid (17% overall, consisted of a single double bond isomer): δ (CDCI3) inter alia 5.24 (1H, d, J 17.4 Hz), 5.39 (1H, d, J 11.0 Hz), 5.71 (1H, d, J 8.4 Hz), 6.52 (1H, dd, J 17.4 and 11.0 Hz), 6.68 (1H, t, J 2.5 Hz), 7.40 (1H, s); MS (+ve ion electrospray) m/z 513 (MH+, 100%).
Example 21 * {(l-Aza-bicyclo[2.2.2]oct-3-yl)-acetyI}-carbamic acid mutilin 14-ester
Ethyl (l-aza-bicyclo[2.2.2]oct-3-yl)-acetate (European Patent 363085, Oct 1988) was hydrolysed by reflux for 5 hours in 8M hydrochloric acid. The resulting (1aza-bicyclo[2.2.2]oct-3-yl)-acetic acid hydrochloride was used to prepare the title compound as a solid (9% overall): δ (CDCI3) inter alia 3.32 (1H, d), 5.0-5.4 (2H, m), 5.61 (1H, d), 6.40 (1H, dd).
AP/P/ 9 7/01047
P31583
AP ϋ Ο Ο 8 7 2
Reference Examples
Example 87 of PCT/EP96/05874. Mutilin 14-[N-(l-ethyl-piperidin-4-oyl)]carbamate
Step 1. Ethyl 1-ethyl-isonipecotate
Ethyl isonipecotate (6.28 g) in ethanol (35 ml) was treated with ethyl iodide (6.86 g) and powdered potassium carbonate (10 g). The mixture was stirred and heated under reflux for 20 hours. The mixture was cooled to room temperature and the solid was removed by filtration and was washed with ethanol (2x10 ml). The ethanol was removed from the filtrate by evaporation under reduced pressure, and the resulting residue was partitioned'between chloroform (100 ml) and water (50 ml). The organic layer was separated, washed with saturated sodium chloride solution, and dried (sodium sulphate). The solvent was removed by evaporation under reduced pressure to give the title compound as a yellow oil (6.62 g);
MS(EI) m/z 185 (M+).
Step 2. 1-Ethyl-isonipecotic acid hydrochloride
Ethyl 1-ethyl-isonipecotate (5.5 g) was dissolved in water (22 ml)/ c.HCl (39 ml) and the solution was heated under reflux for 4 hours. The solvent was removed by evaporation under reduced pressure. The residue was dissolved in water (30 ml), and the water was removed by evaporation under reduced pressure. The residue was triturated with toluene (50 ml), and the toluene was removed by evaporation under reduced pressure to give a solid which was dried in vacuo for 18 hours. The title compound was thus obtained as a white powder (5.4 g); MS(EI) m/z 157 (M+).
AP/P/ 97/0 1047
P31583
AP Ο Ο Ο 8 7 2
Step 3. (3R)-3-Deoxo-ll-deoxy-3-methoxy-ll-oxo-4-epi-mutilin 14-[Ν-(1ethyl-piperidin-4-oyl)]-carbamate
-Ethyl-isonipecotic acid hydrochloride (0.95 g) was suspended in thionvl 5 chloride (8 ml) and the mixture was stirred and heated under reflux for 3 hours to give a clear yellow solution. The thionyl chloride was removed by evaporation under reduced pressure and the resulting residue was suspended in toluene (5 ml) and the toluene was removed by evaporation under reduced pressure to give 1-ethyl-isonipecotoyl chloride hydrochloride as a white solid.
The acid chloride was suspended in dry dichloromethane (20 ml) and silver cyanate (1.5 g) was added. The mixture was stirred and heated under reflux for 1 hour. The mixture was cooled to room temperature and (3R)-3-deoxo-l l-deoxy-3• methoxy-1 l-oxo-4-epi-mutilin (1 g) and triethylamine (0.5 g) were added. The mixture was stirred at room temperature for 16 hours. The mixture was diluted with ethyl acetate (50 ml) and the solid was removed by filtration. The filtrate was washed with saturated sodium bicarbonate and saturated sodium chloride. The solution was dried (sodium sulphate), and the solvent was removed by evaporation under reduced pressure to give a yellow gum. The gum was chromatographed on silica gel using 1:3 ethyl acetate/ chloroform and 1:9:90 ammonia solution (35%)/ methanol/ dichloromethane to give the title compound as a colourless gum (134 mg); 1H NMR (CDCB) inter alia 2.88 (2H, q, J 6.5 Hz), 3.08 (3H, m), 3.22 (3H, s), 3.42 (1H, m), 5.04 (1H, d, J 17.5 Hz), 5.33 (1H, d, J 10.7 Hz), 5.74 (1H, d, J 9.9 Hz), 6.63 (1H, dd, J 17.5, 10.7 Hz), 7.47 (1H, s).
Step 4. Mutilin 14-[N-(l-ethyl-piperidin-4-oyl)]-carbamate (3R)-3-Deoxo-l l-deoxy-3-methoxy-1 l-oxo-4-epi-mutilin 14-[N-(l-ethylpiperidin-4-oy 1)]-carbamate (110 mg) in 1,4-dioxane (0.7 ml) was treated with c.HCl (0.7 ml) and the solution was kept at room temperature for 2.5 hours. The
AP/P/ 97 / 0 1 0 47
P31583
ΑΡΟ00872 solution was diluted with water (10 ml) and washed with dichioromethane (10 ml). The aqueous phase was basified by careful addition of solid potassium carbonate and the resulting mixture (pH 10) was extracted with chloroform (3 x 10 ml). The organic extract was dried (sodium sulphate) and the solvent was removed by evaporation under reduced pressure to give the title compound as a white solid (80 mg); 1HNMR(CDC13) inter alia 1.12 (3H, t, J 7.1 Hz). 2.48 (2H, q, J 7.1 Hz), 2.97 (3H, m), 3.37 (1H, dd, J 10.3, 6.6 Hz), 5.24 (1H, d, J 17.5 Hz), 5.37 (1H, d, J 11 Hz), 5.70 (1H, d, J 8.4 Hz), 6.50 (1H, dd, J 17.5, 11 Hz). 7.35 (1H, s); MS(EI) m/z 502 (M+).
Example 161 of PCT/EP96/05874. Mutilin 14-[N-(Nmethylnipecotyl)carbamate]
Step 1. (3R)-3-Deoxo-ll-deoxy-3-methoxy-ll-oxo-4-epi-mutilin 14-[N-(N15 methylnipecotyl)carbamate] (±)-Ethyl N-methylnipecotate (5.0 g) was dissolved in 5M hydrochloric acid (100 ml) and stirred at room temperature for 16 h. The solution was then evaporated at reduced pressure and the residue re-evaporated 'from toluene (x2). Trituration gave the hydrochloride salt of (±)-N-methylnipecotic acid as a white solid (3.91 g)·
The hydrochloride salt of (±)-N-methylnipecotic acid (1.0 g) was suspended in dichioromethane (25 ml) and stirred at room temperature for 2 h with oxalyl chloride (0.58 ml) and DMF (1 drop). The solvent was then evaporated to yield the hydrochloride salt of N-methylnipecotyl chloride as a pale yellow solid.
The above acid chloride (0.596 g) was suspended in dry dichioromethane and stirred at room temperature for 4 h with (3R)-3-deoxo-l l-deoxy-3-methoxyAP/P/ 9 7/01047
APO00872
P3I583 l-oxo-4-epi-mutilin (0.334 g), silver cyanate (0.450 g) and triethylamine (0.276 ml). The suspension was then filtered through Celite, diluted with ethyl acetate and washed with water and saturated sodium chloride solution. The organic solution was dried (MgSO4), filtered and evaporated to yield the crude product.
Silica gel column chromatography, eluting with a gradient of 0-5% 9:1 methanol/ 35% ammonia solution in dichloromethane gave the title compound as a diastereomeric mixture and as a colourless oil (0.290 g); 1H NMR (CDC13) 0.85 and 0.88 (2xd, all 3H, J6.9Hz), 1.00 (3H, d, J6.4Hz), 1.05-1.85 (m), 1.20 (3H, s), 1.25 (3H, s), 1.9-2.40 (6H, m), 2.32 (3H, 2xs), 2.48 (1H. m), 2.69(1H, broad res.),
2.80-2.98 (3H, broad q,), 3.22 (3H, s), 3.40-3.53 (1H, m), 4.98 (1H, d, J17.6Hz),
5.29 (1H, d, J10.7Hz), 5.62-5.72 (1H, 2xd, J9.9Hz) and 6.78-6.91 (lH,m); MS (El) m/z 503.
rf
Step 2. Mutilin 14-[N-(N-methyInipecotyI)carbamate]
The product from step 1, (0.250 g) in 1,4-dioxan (3.0 ml) was stirred at room temperature for 4 h with cone, hydrochloric acid (2.0 ml). The solution was then diluted with ethyl acetate and neutralized with saturated sodium hydrogen carbonate solution. The organic solution was washed with saturated sodium chloride solution, dried (MgSO4) and evaporated to yield the crude product. After purification by silica gel chromatography, eluting with a gradient of 0-5% 9.T methanol/35% ammonia solution in dichloromethane, the title compound was isolated as a diastereoisomeric mixture and as a white foam, (0.205 g); 1H NMR (CDC13) 0.78 (3H, 2xd, J6.7 Hz), 0.89 (3H, d, J7.0Hz), 1.19 (3H, s), 1.35-2.40 (m), 1.47 (3H, s), 2.30 (3H, 2xs),2.63-2.90 (2H, broad res.), 3.35 (1H, broad res.),
5.22 (1H, d, J17.4Hz), 5.39 (1H, dd, Jl.4,11.0Hz), 5.60-5.72 (1H, 2xd, J8.5 Hz), and 6.63 (1H, dd, J11.0,17.4Hz); MS (El) m/z 488.
AP/P/ 9 7/01047
P31583
AP 0 ΰG 8 7 2 tfevtag mwr particularly 3e»cribeB and
MDertaioed tny/our said invention and la aHkar manner the samr is η» be jicrfornJej l/V· declare that what I/we daitn « —

Claims (9)

  1. CLAIMS:
    1. A compound of formula (3), or a pharmaceutically acceptable salt or derivative thereof:
    in which:
    Rl is vinyl or ethyl; and ,
    R- is a group r3, R4CH2', or r5r6c=CH-; wherein each of R^ and R4 is an
    10 azabicyclic ring system or R$ and R^ together with the carbon atom to which they are attached form an azabicyclic ring system.
  2. 2. A compound according to claim 1, wherein each azabicyclic ring system is selected from the group consisting of azabicyclo[2.2.2]octyl,
    15 azabicyclo[2.2.1]heptyl, azabicyclo[3.2.1]octyl, azabicyclo[4.4.0]decyl, quinuclidinyl, azabicyclo[3.2.1]octenyl, and azabicyclo[3.3.1]non-5-yl.
  3. 3. A compound according to claim 1 or 2, substantially as hereinbefore described in any one of the Examples.
  4. 4. A method for preparing a compound according to any one of the preceding claims, which comprises reacting a compound of formula (4) where X is hydrogen or a hydroxyl protecting group, or a compound of formula (
  5. 5), with an acyl isocyanate of formula R^CONCO, R4CH2CONCO, or r5r6c=CHCONCO:
    AP/P/ 9 7 / 0 10 47
    P31583
    AP Ο Ο Ο β 7 2
    ¢/ OX Cz 0 HO-.Z Z...... HO-./ ...... \MeO‘4- /___ 0 (4) (5) 5. A process according to claim 4, which comprises reacting a compound of formula (4) with a compound of formula R^COCl, R4CH2COC1, or r5r6c=CHCOC1 in the presence of silver cyanate and a base, wherein each of
    R? to R.6 is protected where appropriate, and thereafter carrying out one or more of the following steps in any desired order:
    • deprotecting a group X to generate a hydroxyl group at position 11, • deprotecting a protected group R^ to R^ , • converting one group R^ to to another group R^ to R0, and • hydrogenating the vinyl group at position 12 to form an ethyl group.
  6. 6. A process according to claim 4, which comprises reacting a compound of 15 formula (5) with a compound of formula R^COCl, R^CHqCOCl, or r5r6c=CHCOC1 in the presence of silver cyanate and a base, wherein each of to is protected where appropriate, and thereafter carrying out one or more of the following steps in any desired order:
    • treating the product with acid to give a compound of formula (3),
    20 · deprotecting a protected group R? to , • converting one group to to another group to R^, and • hydrogenating the vinyl group at position 12 to form an ethyl group.
    AP/P/ »7/01047
    P31583
    APO 0 0 8 7 2
  7. 7. A pharmaceutical composition comprising a compound according to claim 1, 2 or 3, together with a pharmaceutically acceptable carrier or excipient.
  8. 8. A method of treating microbial infections in animals, especially in humans and in domesticated mammals, which comprises administering an antimicrobially effective amount of a compound according to claim 1, 2 or 3, or a composition according to claim 7, to a patient in need thereof.
  9. 9. Use of a compound according to claim 1,2 or 3, in the preparation of a medicament composition for use in the treatment of microbial infections.
APAP/P/1997/001047A 1996-08-02 1997-07-21 Azabicyclic carbamoyloxy mutilin derivatives for antibacterial use. AP872A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9616305.0A GB9616305D0 (en) 1996-08-02 1996-08-02 Novel compounds
PCT/EP1996/005874 WO1997025309A1 (en) 1996-01-03 1996-12-19 Carbamoyloxy derivatives of mutiline and their use as antibacterials
GBGB9712963.9A GB9712963D0 (en) 1997-06-19 1997-06-19 Novel compounds

Publications (2)

Publication Number Publication Date
AP9701047A0 AP9701047A0 (en) 1997-07-31
AP872A true AP872A (en) 2000-09-28

Family

ID=26309807

Family Applications (1)

Application Number Title Priority Date Filing Date
APAP/P/1997/001047A AP872A (en) 1996-08-02 1997-07-21 Azabicyclic carbamoyloxy mutilin derivatives for antibacterial use.

Country Status (25)

Country Link
US (1) US6121281A (en)
EP (1) EP0934316B1 (en)
JP (1) JP4204069B2 (en)
KR (1) KR20000029748A (en)
CN (1) CN1231665A (en)
AP (1) AP872A (en)
AR (1) AR010984A1 (en)
AT (1) ATE226203T1 (en)
AU (1) AU4203697A (en)
BR (1) BR9711008A (en)
CA (1) CA2262460A1 (en)
CZ (1) CZ29399A3 (en)
DE (1) DE69716455T2 (en)
ES (1) ES2182114T3 (en)
HU (1) HUP0001741A3 (en)
ID (1) ID17421A (en)
IL (1) IL128319A0 (en)
MA (1) MA24355A1 (en)
NO (1) NO990463D0 (en)
NZ (1) NZ333926A (en)
PE (1) PE99098A1 (en)
PL (1) PL331470A1 (en)
TR (1) TR199900194T2 (en)
UY (1) UY24653A1 (en)
WO (1) WO1998005659A1 (en)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UY25225A1 (en) * 1997-10-29 2000-12-29 Smithkline Beecham Plc PLEUROMUTILINE DERIVATIVES USEFUL AS ANTIMICROBIAL AGENTS
GB9807503D0 (en) * 1998-04-07 1998-06-10 Smithkline Beecham Plc Use
GB9817029D0 (en) * 1998-08-05 1998-09-30 Smithkline Beecham Plc Novel compounds
WO2000037074A1 (en) * 1998-12-18 2000-06-29 Smithkline Beecham Plc Mutilin 14-ester derivatives having antibacterial activity
EP1268443B1 (en) 2000-04-04 2009-07-29 Smithkline Beecham Plc 2-hydroxy-mutilin carbamate derivatives for antibacterial use
FR2812635B1 (en) * 2000-08-01 2002-10-11 Aventis Pharma Sa NOVEL HETEROCYCLIC COMPOUNDS, PREPARATION AND USE AS MEDICAMENTS IN PARTICULAR AS ANTI-BACTERIALS
GB0024811D0 (en) * 2000-10-10 2000-11-22 Smithkline Beecham Plc Novel compounds
FR2835186B1 (en) * 2002-01-28 2006-10-20 Aventis Pharma Sa NOVEL HETEROCYCLIC COMPOUNDS ACTIVE AS BETA-LACTAMASES INHIBITORS
GB0218578D0 (en) * 2002-08-09 2002-09-18 Glaxo Group Ltd Novel method
GB0308114D0 (en) * 2003-04-08 2003-05-14 Glaxo Group Ltd Novel compounds
JPWO2006070671A1 (en) * 2004-12-27 2008-06-12 杏林製薬株式会社 12-substituted mutilin derivatives
GB0504314D0 (en) 2005-03-02 2005-04-06 Glaxo Group Ltd Novel polymorph
JP5322927B2 (en) 2007-05-24 2013-10-23 杏林製薬株式会社 A mutilin derivative having a heteroaromatic carboxylic acid structure at the 14-position substituent.
JP6170990B2 (en) * 2015-12-10 2017-07-26 東京応化工業株式会社 Compound
WO2018058534A1 (en) 2016-09-30 2018-04-05 华南农业大学 Pleuromutilin derivative having 2-amino phenyl mercaptan side chain, preparation method therefor, and uses thereof
TWI762573B (en) 2017-02-10 2022-05-01 奧地利商納畢瓦治療有限責任公司 Purification of pleuromutilin
ES2962986T3 (en) * 2017-12-07 2024-03-22 Amplyx Pharmaceuticals Inc Antifungal agents derived from heterocycle-substituted pyridine
CN116396245B (en) * 2023-04-18 2025-08-26 西北工业大学宁波研究院 Pleuromutilin derivatives and preparation methods thereof

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SK91098A3 (en) * 1996-01-03 1999-02-11 Smithkline Beecham Plc Carbamoyloxy derivatives of mutiline and their use as antibacterials

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
JOURNAL OF ANTIBIOTICS, vol. 29, no. 9, 1976, TOKYO JP, pages 923-927 TABLE 1 *

Also Published As

Publication number Publication date
ES2182114T3 (en) 2003-03-01
NZ333926A (en) 2000-05-26
US6121281A (en) 2000-09-19
AR010984A1 (en) 2000-08-02
WO1998005659A1 (en) 1998-02-12
JP4204069B2 (en) 2009-01-07
KR20000029748A (en) 2000-05-25
UY24653A1 (en) 1998-01-27
HUP0001741A3 (en) 2000-11-28
BR9711008A (en) 1999-08-17
TR199900194T2 (en) 1999-03-22
MA24355A1 (en) 1998-07-01
CA2262460A1 (en) 1998-02-12
EP0934316B1 (en) 2002-10-16
NO990463L (en) 1999-02-01
CN1231665A (en) 1999-10-13
DE69716455D1 (en) 2002-11-21
ATE226203T1 (en) 2002-11-15
PE99098A1 (en) 1999-03-10
AU4203697A (en) 1998-02-25
HUP0001741A2 (en) 2000-10-28
EP0934316A1 (en) 1999-08-11
NO990463D0 (en) 1999-02-01
CZ29399A3 (en) 1999-06-16
ID17421A (en) 1997-12-24
DE69716455T2 (en) 2003-06-26
IL128319A0 (en) 2000-01-31
PL331470A1 (en) 1999-07-19
AP9701047A0 (en) 1997-07-31
JP2000515532A (en) 2000-11-21

Similar Documents

Publication Publication Date Title
AP872A (en) Azabicyclic carbamoyloxy mutilin derivatives for antibacterial use.
EP1930330B1 (en) Pleuromutilin derivatives as antimicrobials
US6239175B1 (en) Carbamoyloxy derivatives of mutiline and their use as antibacterials
AU2001263827B2 (en) 2-hydroxy-mutilin carbamate derivatives for antibacterial use
EP1538150B1 (en) Novel pleuromutilin derivatives
US7045524B2 (en) Pleuromutilin derivatives with antimicrobial activity
EP0161541B1 (en) 6-[1-Hydroxyethyl]-2-SR8-1-methyl-1-carba-dethiapen-2-em-3-carboxylic acids
WO2000007974A1 (en) 2-fluoro mutilin derivatives
WO2001014310A1 (en) PLEUROMUTILIN β-KETOESTERS
WO2000073287A1 (en) Isoxazoline carboxylate derivatives of mutiline and their use as antibacterials
HK1078865A (en) Novel pleuromutilin derivatives
HK1071128A (en) Pleuromutlin derivatives as antimicrobials
ZA200207912B (en) 2-hydroxy-mitilin carbamate derivatives for antibacterial use.
HK1116784A (en) Pleuromutilin derivatives as antimicrobials
JP2000086667A (en) Carbapenem compounds
HK1031376B (en) Pleuromutilin derivatives as antimicrobials